周恒
心内
副教授，副主任医师，硕士生导师
副教授，副主任医师，硕士生导师
导师介绍
| 姓名 | 周恒 |
| 出生年月 | 1984年10月 |
| 单位 | 武汉大学人民医院心血管内科 |
| 所属学科 | 临床医学-内科学 |
| 职务、职称及头衔 | 副教授，副主任医师，硕士生导师 |
| hengzhou@whu.edu.cn | |
| 联系方式 | 13477098557 |
| 研究方向 | 心肌重构与心力衰竭的发病机制与临床防治 |
| 个人简介 | 主要从事心血管疾病的诊治与科研工作，在心肌重构与心力衰竭领域进行了长期研究。以第一/通讯作者发表学术论文27篇，其中SCI论文19篇，包括Hypertension、Basic Research in Cardiology等心血管领域国际著名期刊。主持国家自然科学基金2项、中央高校基本科研业务费专项资金项目1项、湖北省卫健委科研项目一项，参与2项国家自然科学基金重点项目以及多项国家、省部级科研项目。获湖北省科学技术进步奖一等奖2项、武汉市科学技术进步奖一等奖1项，学术论文获湖北省自然科学优秀学术论文一等奖1项。 |
| 学术任职与荣誉 |
海峡两岸医药卫生交流协会老年分会青委会委员 《中华生物医学工程杂志》中青年编委 Disease Markers期刊学术编辑 Ebiomedicine等期刊审稿人 |
| 教育履历 |
2002.09-2007.06武汉大学医学部临床医学专业本科生获学士学位 2007.09-2012.06武汉大学第一临床学院内科学硕博连读研究生获博士学位 |
| 工作履历 |
2012.07-2012.11武汉大学人民医院心血管内科医师 2012.11-2015.11武汉大学人民医院心血管内科主治医师 2015.11-至今武汉大学人民医院心血管内科副主任医师 2016.11-至今武汉大学人民医院心血管内科副教授 |
| 成果获奖 |
1.《心力衰竭的结构重构及其防治》2019年获湖北省科技进步一等奖 2.《心肌重构的发病基础与临床防治》2013年获湖北省科技进步一等奖 3.《心肌重构的发病基础与临床防治》2013年获武汉市科技进步一等奖 |
| 代表性论著 |
1．Jin YG, Zhou H, Fan D, Che Y, Wang
ZP, Wang SS, Tang QZ. TMEM173 protects against pressure overload-induced
cardiac hypertrophy by modulating autophagy. J Cell Physiol. 2020 Dec 23.
doi: 10.1002/jcp.30223. 2．Zhou H, Li N, Yuan Y, Jin YG, Wu Q, Yan L, Bian ZY, Deng W, Shen DF, Li H, Tang QZ. Leukocyte immunoglobulin-like receptor B4 protects against cardiac hypertrophy via SHP-2-dependent inhibition of the NF-κB pathway. J Mol Med (Berl). 2020;98(5):691-705. 3．Li N,Zhou H, Wu H, Wu Q, Duan M, Deng W, Tang Q. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3. Redox Biol. 2019;24:101215. 4．Duan MX,Zhou H, Wu QQ, Liu C, Xiao Y, Deng W, Tang QZ. Andrographolide Protects against HG-Induced Inflammation, Apoptosis, Migration, and Impairment of Angiogenesis via PI3K/AKT-eNOS Signalling in HUVECs. Mediators Inflamm. 2019;2019:6168340. 5．Li N, Li L, Wu H,Zhou H. Antioxidative Property and Molecular Mechanisms Underlying Geniposide-Mediated Therapeutic Effects in Diabetes Mellitus and Cardiovascular Disease. Oxid Med Cell Longev. 2019;2019:7480512. 6．Li N, Zhou H, Ma ZG, Zhu JX, Liu C, Song P, Kong CY, Wu HM, Deng W, Tang QZ. Geniposide Alleviates Isoproterenol-Induced Cardiac Fibrosis Partially via SIRT1 Activation in vivoandin vitro. Front Pharmacol. 2018;9:854. 7．Zhou H, Li N, Yuan Y, Jin YG, Guo H, Deng W, Tang QZ. Activating transcription factor 3 in cardiovascular diseases: a potential therapeutic target. Basic Res Cardiol. 2018;113(5):37. 8．Li N, Zhou H, Tang Q. miR-133: A Suppressor of Cardiac Remodeling? Front Pharmacol. 2018;9:903. 9．Li N, Zhou H, Tang Q. Red Blood Cell Distribution Width: A Novel Predictive Indicator for Cardiovascular and Cerebrovascular Diseases. Dis Markers. 2017;2017:7089493. 10．Yuan Y, Zhou H, Wu QQ, Li FF, Bian ZY, Deng W, Zhou MQ, Tang QZ. Puerarin attenuates the inflammatory response and apoptosis in LPS-stimulated cardiomyocytes. Exp Ther Med. 2016;11(2):415-420. 11．Zhou H, Yuan Y, Ni J, Guo H, Deng W, Bian ZY, Tang QZ. Pleiotropic and puzzling effects of ATF3 in maladaptive cardiac remodeling. Int J Cardiol. 2016;206:87-88. 12．Zhou H, Yuan Y, Liu Y, Ni J, Deng W, Bian ZY, Dai J, Tang QZ. Icariin protects H9c2 cardiomyocytes from lipopolysaccharide induced injury via inhibition of the reactive oxygen species dependent c Jun N terminal kinases/nuclear factor-κB pathway. Mol Med Rep, 2015, 11(6): 4327-4332. 13．Zhou H, Ni J, Yuan Y, Deng W, Bian ZY, Tang QZ. Soluble ST2 may possess special superiority as a risk predictor in heart failure patients. Int J Cardiol, 2015, 186, 146-147. 14．Zhou H, Guo H, Zong J, Dai J, Yuan Y, Bian ZY, Tang QZ. ATF3 regulates multiple targets and may play a dual role in cardiac hypertrophy and injury. Int J Cardiol. 2014, 174(3):838-839. 15．Zhou H, Yuan Y, Liu Y, Deng W, Zong J, Bian ZY, Dai J, Tang QZ. Icariin attenuates angiotensin II-induced hypertrophy and apoptosis in H9c2 cardiomyocytes by inhibiting reactive oxygen species-dependent JNK and p38 pathways. Exp Ther Med. 2014, 7(5):1116-1122. 16．Jiang DS, Liu Y, Zhou H, Zhang Y, Zhang XD, Zhang XF, Chen K, Gao L, Peng J, Gong H, Chen Y, Yang Q, Liu PP, Fan GC, Zou Y, Li H. Interferon regulatory factor 7 functions as a novel negative regulator of pathological cardiac hypertrophy. Hypertension. 2014, 63(4):713-722. 17．Zhou H, Yang HX, Yuan Y, Deng W, Zhang JY, Bian ZY, Zong J, Dai J, Tang QZ. Paeoniflorin attenuates pressure overload-induced cardiac remodeling via inhibition of TGFβ/Smads and NF-κB pathways. J Mol Histol. 2013, 44(3):357-367. 18．Zhou H, Bian ZY, Zong J, Deng W, Yan L, Shen DF, Guo H, Dai J, Yuan Y, Zhang R, Lin YF, Hu X, Li H, Tang QZ. Stem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overload. Hypertension. 2012;60(3):802-809. 19．Zhou H, Shen DF, Bian ZY, Zong J, Deng W, Zhang Y, Guo YY, Li H, Tang QZ. Activating transcription factor 3 deficiency promotes cardiac hypertrophy, dysfunction, and fibrosis induced by pressure overload.PLoS One. 2011;6(10):e26744. |
| Name | HENG ZHOU |
| Date of birth | October,1984 |
| Department | Cardiovascular Department，Renmin Hospital,Wuhan University. |
| Title | Vice Director, Vice Professor, Master Tutor |
| hengzhou@whu.edu.cn | |
| TEL | 13477098557 |
| Research Direction | Mechanism and treatment of cardiac remodeling and heart failure |
| Personal Profile | He is mainly engaged in the diagnosis and treatment of cardiovascular diseases, especially cardiac remodeling and heart failure. There are 27 research papers published by the first author/corresponding author, including 19 SCI papers and some of them were published in the famous journals such as Hypertension and Basic Research in Cardiology. He has been awarded 2 items of the National Natural Science Foundation, 1 items of the Fundamental Research Funds for the Central Universities, and the Provincial Health Department. He also won the First Class Prizes of Hubei Provincial Scientific and Technological Progress Award twice, and the First Class Prizes of Wuhan Municipal Scientific and Technological Progress Award once. |
| Selected Publications |
1．Jin YG, Zhou H, Fan D, Che Y, Wang
ZP, Wang SS, Tang QZ. TMEM173 protects against pressure overload-induced
cardiac hypertrophy by modulating autophagy. J Cell Physiol. 2020 Dec 23.
doi: 10.1002/jcp.30223. 2．Zhou H, Li N, Yuan Y, Jin YG, Wu Q, Yan L, Bian ZY, Deng W, Shen DF, Li H, Tang QZ. Leukocyte immunoglobulin-like receptor B4 protects against cardiac hypertrophy via SHP-2-dependent inhibition of the NF-κB pathway. J Mol Med (Berl). 2020;98(5):691-705. 3．Li N,Zhou H, Wu H, Wu Q, Duan M, Deng W, Tang Q. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3. Redox Biol. 2019;24:101215. 4．Duan MX,Zhou H, Wu QQ, Liu C, Xiao Y, Deng W, Tang QZ. Andrographolide Protects against HG-Induced Inflammation, Apoptosis, Migration, and Impairment of Angiogenesis via PI3K/AKT-eNOS Signalling in HUVECs. Mediators Inflamm. 2019;2019:6168340. 5．Li N, Li L, Wu H,Zhou H. Antioxidative Property and Molecular Mechanisms Underlying Geniposide-Mediated Therapeutic Effects in Diabetes Mellitus and Cardiovascular Disease. Oxid Med Cell Longev. 2019;2019:7480512. 6．Li N, Zhou H, Ma ZG, Zhu JX, Liu C, Song P, Kong CY, Wu HM, Deng W, Tang QZ. Geniposide Alleviates Isoproterenol-Induced Cardiac Fibrosis Partially via SIRT1 Activation in vivoandin vitro. Front Pharmacol. 2018;9:854. 7．Zhou H, Li N, Yuan Y, Jin YG, Guo H, Deng W, Tang QZ. Activating transcription factor 3 in cardiovascular diseases: a potential therapeutic target. Basic Res Cardiol. 2018;113(5):37. 8．Li N, Zhou H, Tang Q. miR-133: A Suppressor of Cardiac Remodeling? Front Pharmacol. 2018;9:903. 9．Li N, Zhou H, Tang Q. Red Blood Cell Distribution Width: A Novel Predictive Indicator for Cardiovascular and Cerebrovascular Diseases. Dis Markers. 2017;2017:7089493. 10．Yuan Y, Zhou H, Wu QQ, Li FF, Bian ZY, Deng W, Zhou MQ, Tang QZ. Puerarin attenuates the inflammatory response and apoptosis in LPS-stimulated cardiomyocytes. Exp Ther Med. 2016;11(2):415-420. 11．Zhou H, Yuan Y, Ni J, Guo H, Deng W, Bian ZY, Tang QZ. Pleiotropic and puzzling effects of ATF3 in maladaptive cardiac remodeling. Int J Cardiol. 2016;206:87-88. 12．Zhou H, Yuan Y, Liu Y, Ni J, Deng W, Bian ZY, Dai J, Tang QZ. Icariin protects H9c2 cardiomyocytes from lipopolysaccharide induced injury via inhibition of the reactive oxygen species dependent c Jun N terminal kinases/nuclear factor-κB pathway. Mol Med Rep, 2015, 11(6): 4327-4332. 13．Zhou H, Ni J, Yuan Y, Deng W, Bian ZY, Tang QZ. Soluble ST2 may possess special superiority as a risk predictor in heart failure patients. Int J Cardiol, 2015, 186, 146-147. 14．Zhou H, Guo H, Zong J, Dai J, Yuan Y, Bian ZY, Tang QZ. ATF3 regulates multiple targets and may play a dual role in cardiac hypertrophy and injury. Int J Cardiol. 2014, 174(3):838-839. 15．Zhou H, Yuan Y, Liu Y, Deng W, Zong J, Bian ZY, Dai J, Tang QZ. Icariin attenuates angiotensin II-induced hypertrophy and apoptosis in H9c2 cardiomyocytes by inhibiting reactive oxygen species-dependent JNK and p38 pathways. Exp Ther Med. 2014, 7(5):1116-1122. 16．Jiang DS, Liu Y, Zhou H, Zhang Y, Zhang XD, Zhang XF, Chen K, Gao L, Peng J, Gong H, Chen Y, Yang Q, Liu PP, Fan GC, Zou Y, Li H. Interferon regulatory factor 7 functions as a novel negative regulator of pathological cardiac hypertrophy. Hypertension. 2014, 63(4):713-722. 17．Zhou H, Yang HX, Yuan Y, Deng W, Zhang JY, Bian ZY, Zong J, Dai J, Tang QZ. Paeoniflorin attenuates pressure overload-induced cardiac remodeling via inhibition of TGFβ/Smads and NF-κB pathways. J Mol Histol. 2013, 44(3):357-367. 18．Zhou H, Bian ZY, Zong J, Deng W, Yan L, Shen DF, Guo H, Dai J, Yuan Y, Zhang R, Lin YF, Hu X, Li H, Tang QZ. Stem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overload. Hypertension. 2012;60(3):802-809. 19．Zhou H, Shen DF, Bian ZY, Zong J, Deng W, Zhang Y, Guo YY, Li H, Tang QZ. Activating transcription factor 3 deficiency promotes cardiac hypertrophy, dysfunction, and fibrosis induced by pressure overload.PLoS One. 2011;6(10):e26744. |
武汉大学人民医院
湖北省人民医院